At Corion Biotech we are committed to develop innovative therapeutic solutions for women’s health.

The technology is based on a specific cell population derived from the human term placenta known as Placental Mesenchymal Stromal Cells (hPDMSCs).

By our proprietary technology, we exploit the unique PDMSCs’s therapeutic abilities to develop our “Cell Therapy without Cells”.

The new approach maintains the effectiveness of cell therapy avoiding the risk of direct administration of living allogenic cells to patients.

We strongly believe that our approach is the most ethical, safe and effective solution present in the Advanced Therapy Medicinal Products panorama.


Preeclampsia affects 3-8% of all pregnancies worldwide, thus being the main cause of fetal-maternal mortality and morbidity.

A new drug for Preeclampsia represents an important improvement for the health of millions of mothers and children with a substantial saving for sanitary systems in developed countries.


Epithelial cancers affecting ovarian and breast tissues represent the first cause of death among all gynecological cancers.
Although most patients achieve complete clinical response following standard treatments, a very high percentage of them eventually relapse. Therefore, it is mandatory to develop new therapeutic strategies.

About us

Corion Biotech is an innovative startup founded in December 2012 as an academic spin-off of the University of Turin


Our team has a record of more than 300 publications in international indexed medical-scientific journals in the field of Obstetrics & Gynaecology.

For information


Chief Scientific Officer: Alessandro Rolfo

Chief Operation Officer: Carlo Cavallero


Go to Top